A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
Keywords: لوسمی مزمن میلوئیدی در بحران انفجار; AML; acute myeloid leukemia; ALL; acute lymphoblastic leukemia; CR; complete response; PR; partial response; ara-C; cytarabine; MDR1; multidrug resistance; Pgp; P-glycoprotein; SWOG; southwest oncology group; DLT; dose limiting toxicity; MTD; maximum tole